BFB
LIVE

Serial Number

99218536

Owner

Bluefin Biomedicine, Inc.

Attorney

Keith Toms, Esq.

Filing Date

Jun 4, 2025

Add to watchlist:

No watchlists yet
View on USPTO

BFB Trademark

Serial Number: 99218536

BFB is a trademark filed by Bluefin Biomedicine, Inc. on June 4, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Bluefin Biomedicine, Inc. (4 trademarks)

32 Tozer Road
Beverly, MA 01915

Entity Type: 03

Trademark Details

Filing Date

June 4, 2025

Registration Date

Not Registered

Published for Opposition

November 25, 2025

Goods & Services

Antibodies for medical purposes; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders

Pharmaceutical research and development; Research and development services in the field of antibodies; Providing medical and scientific research information; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of proteomics, transcriptomics, and bioinformatics

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 20, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 24, 2025 CNSA
ASSIGNED TO EXAMINER
Oct 24, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 10, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jun 4, 2025 MAFR
NEW APPLICATION ENTERED
Jun 4, 2025 NWAP